MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.220
-0.060
-1.40%
After Hours: 4.230 +0.01 +0.24% 16:47 02/26 EST
OPEN
4.220
PREV CLOSE
4.280
HIGH
4.380
LOW
4.150
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
5.70
52 WEEK LOW
1.420
MARKET CAP
455.89M
P/E (TTM)
-5.0691
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Thinking about buying stock in GameStop, AMC Entertainment, Dynatronics Corp, Selecta Biosciences, or vTv Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, DYNT, SELB, and VTVT.
PR Newswire - PRF · 1d ago
GME, AMC, TNXP and NGA among premarket gainers
Pandion Therapeutics (PAND) +132% as Merck to acquire the company for $2.0B.Koss Corporation (KOSS) +92%.Dynatronics Corporation (DYNT) +91% on extension of key distribution agreement.GameStop Corp. (GME) +72%.AmeriServ Financial (ASRV) +33%.Socket Mobile ...
Seekingalpha · 1d ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 1d ago
CCRN, TNDM, PGNY and NMRK among after-hours movers
Gainers: [[CCRN]] +24.3%. [[SELB]] +19.6%. [[TRUE]] +16.8%. [[TNDM]] +13.0%. [[RCII]] +10.9%.Losers: [[IFRX]] -9.7%. [[PGNY]] -8.7%. [[NMRK]] -8.5%. [[ZVO]] -8.2%. [[CLPS]] -8.1%.
Seekingalpha · 1d ago
BRIEF-Selecta Biosciences Announces Science Advances Publication
reuters.com · 2d ago
Selecta Biosciences Reports 'Science Advances' Published Highlighting Potential Potency, Durability Benefits Of ImmTOR In Gene Therapy
Selecta Biosciences, Inc. (NASDAQ:SELB, &ldquo, Selecta&rdquo, )), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted
Benzinga · 2d ago
Selecta Biosciences' ImmTOR nanoparticles shows promise in gene therapy study
Selecta Biosciences (SELB) announces peer-reviewed publication of a study investigating the effects of the co-administration of ImmTOR nanoparticles to adeno-associated viral ((AAV)) vectors on transgene expression in mice.The data showed
Seekingalpha · 2d ago
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR in Gene Therapy
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA expression - - Replicated findings supporting ImmTOR’s a...
GlobeNewswire · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SELB. Analyze the recent business situations of Selecta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SELB stock price target is 7.50 with a high estimate of 13.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 144
Institutional Holdings: 53.11M
% Owned: 49.16%
Shares Outstanding: 108.03M
TypeInstitutionsShares
Increased
36
8.48M
New
36
-4.24M
Decreased
23
15.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
Carrie Cox
President/Chief Executive Officer/Director
Carsten Brunn
Chief Financial Officer/Chief Accounting Officer
Bradford Dahms
Chief Operating Officer/Senior Vice President
Lloyd Johnston
Chief Scientific Officer
Takashi Kishimoto
Independent Director
Goran Ando
Independent Director
Timothy Barabe
Independent Director
Scott Myers
Independent Director
Aymeric Sallin
Independent Director
Timothy Springer
Independent Director
Patrick Zenner
  • Dividends
  • Splits
  • Insider Activity
No Data
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SELB stock methods without spending real money on the virtual paper trading platform.